Publication:
The Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa Nephrology Unit

Simple item page
dc.contributor.authorBUKHARI, ANDLEEB
dc.contributor.authorSonmez, Ikbal
dc.contributor.authorKose, Cagla
dc.contributor.authorOKTAN, BURHANEDDİN
dc.contributor.authorAlagoz, Selma
dc.contributor.authorSonmez, Haktan
dc.contributor.authorHussain, Adil
dc.contributor.authorAKKAN, Ahmet Gökhan
dc.contributor.institutionauthorAKKAN, AHMET GÖKHAN
dc.date.accessioned2022-03-29T20:59:18Z
dc.date.available2022-03-29T20:59:18Z
dc.date.issued2022-02-01T00:00:00Z
dc.description.abstractBackground and Objectives: Chronic kidney disease (CKD) is usually linked with polypharmacy and patients are invariably at risk of complex medication regimens. The present study was designed to estimate the potential drug-drug interactions (pDDIs) through the prescription patterns provided to patients of the Nephrology Transplant Unit of Cerrahpasa Medical Faculty patients. Materials and Methods: 96 patients were included in the study. pDDIs among every combination of the prescribed drug were analyzed using the Thomson Reuters Micromedex. Results: We found 149 pDDIs making 2.16 interactions per prescription with incidence rates of 69.7%. Approximately 4.1% of interactions were of significant severity, 75.1% moderate severity, and 20.8% were classified as minor pDDIs. The most frequent interactions were found between iron and aluminum, calcium or magnesium-containing products (21.37%), calcium channel blockers and beta-blockers (8.96%); and aspirin and aluminum, calcium, or magnesium-containing products (7.58%). We identified 42 drug pairs with probability of clinical significance. The most commonly reported clinical outcomes of the pDDIs were hypo- or hypertension (39.24%), decreased drug efficacy (24.05%), and arrhythmia (9.49%). Aluminum, calcium, or magnesium-containing drug products (33.10%) constituted the primary class of drugs involved in interactions. Conclusions: This study showed pharmacodynamics (49%), pharmacokinetics (42.94%) interactions, polypharmacy and gender as determinant of pDDIs. A comprehensive multicenter research is required to decrease the morbidity and ease the state burden.
dc.identifier.doi10.3390/medicina58020183
dc.identifier.pubmed35208508
dc.identifier.scopus85124135998
dc.identifier.urihttp://hdl.handle.net/20.500.12645/30488
dc.identifier.wosWOS:000769018600001
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectchronic kidney disease
dc.subjectdrug-drug interactions
dc.subjecthypertension
dc.subjectpolypharmacy
dc.titleThe Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa Nephrology Unit
dc.typeArticle
dspace.entity.typePublication
local.avesis.id8f115c7e-ff43-418c-b387-9420ea655f8e
local.publication.isinternational1
relation.isAuthorOfPublication3d01b102-caf1-4fba-a467-f358f2f6d3c7
relation.isAuthorOfPublication.latestForDiscovery3d01b102-caf1-4fba-a467-f358f2f6d3c7
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa Nephrology Unit.pdf
Size:
670.28 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler